Logo-jcvtr
Submitted: 22 Dec 2019
Revision: 04 Sep 2020
Accepted: 30 Sep 2020
ePublished: 28 Nov 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2020;12(4): 334-336.
doi: 10.34172/jcvtr.2020.53
PMID: 33510884
PMCID: PMC7828763
Scopus ID: 85106542785
  Abstract View: 850
  PDF Download: 394

Case Series

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series

Sepideh Taghavi 1 ORCID logo, Maryam Chenaghlou 2* ORCID logo, Marzieh Mirtajaddini 3, Ahmad Amin 1, Nasim Naderi 1

1 Rajaie Cardiovascular Medical and Research Center, Tehran, Iran
2 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Cardiovascular Research Center, Kerman University of Medical Sciences, Kerman, Iran
*Corresponding Author: Email: mchenaghlou@yahoo.com

Abstract

Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies. These patients are subjected to receive non-medical therapies including heart transplant or mechanical circulatory support for increasing survival. Considering the low availability and serious complications of these strategies,effective medical therapies for this group of patients would be pivotal for decreasing mortality and morbidity of them. Angiotensin receptor neprilysin inhibitor (ARNI) is a class of drugs approved for ambulatory heart failure patients. ARNI use like other groups of heart failure drugs has not been fully evaluated in end-stage heart failure patients. Herein, we describe four inotrope-dependent heart failure patients. Initiation of ARNI in these patients, lead to discontinuation of inotrope and reducing the need for inotrope in the follow-up period.
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 849

Your browser does not support the canvas element.


PDF Download: 394

Your browser does not support the canvas element.